ACK
TAK icon

Andrew C. Karlinski’s Takeda Pharmaceutical TAK Stock Holding History

Andrew C. Karlinski’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-119
Closed -$2K – 214
2022
Q3 		$2K Buy
119
+2
+2% +$28 ﹤0.01% 236
2022
Q2 		$2K Hold
117
– – ﹤0.01% 269
2022
Q1 		$2K Buy
+117
New +$1.72K ﹤0.01% 263

Other funds holding TAK

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Andrew C. Karlinski's TAK Position: Q4 2022 in Review

Andrew C. Karlinski sold out of Takeda Pharmaceutical (TAK) in Q4 2022, closing a stake of 119 shares — an estimated $2K sold.

Andrew C. Karlinski first reported a position in TAK in Q1 2022 and held it in 3 quarters. The position peaked at $2K in Q3 2022. 281 funds tracked by Wall St. Rank hold TAK as of Q4 2022.

  • Andrew C. Karlinski reported no remaining Takeda Pharmaceutical position as of Q4 2022 after selling out during the quarter.
  • Andrew C. Karlinski sold 119 Takeda Pharmaceutical shares in Q4 2022, an estimated $2K.
  • Andrew C. Karlinski first reported a position in Takeda Pharmaceutical in Q1 2022 and held it in 3 quarters.
  • Andrew C. Karlinski's Takeda Pharmaceutical position peaked at $2K in Q3 2022.
  • 281 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2022.

Based on Andrew C. Karlinski's 13F filing for Q4 2022.